Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study.
abscopal effect
anti-PD-1
anti-PD-L1
immune checkpoint inhibitors
immunosuppression
immunotherapy
palliative radiotherapy
Journal
Biomedical reports
ISSN: 2049-9434
Titre abrégé: Biomed Rep
Pays: England
ID NLM: 101613227
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
10
09
2019
accepted:
06
11
2019
entrez:
14
1
2020
pubmed:
14
1
2020
medline:
14
1
2020
Statut:
ppublish
Résumé
In the present study, the influence of purely palliative radiotherapy (pRT) on the outcomes of patients with advanced cancer undergoing immune checkpoint blockade was evaluated. Patients were stratified into three groups: Patients who had received pRT within 6 months prior to the initiation of immunotherapy (previous pRT); patients who received pRT during immunotherapy (concurrent pRT); and patients who did not receive RT prior to or during immunotherapy (no RT group), and these groups were compared. The median overall survival (mOS), median progression free survival (mPFS) and median time-to-treatment failure (mTTF) for the previous pRT group were significantly shorter compared with the no RT group (mOS, 3.6 vs. 12.1 months, respectively, P=0.0095; mPFS 1.8 vs. 5.4 months, respectively, P=0.0016; mTTF 1.8 vs. 5.7 months, respectively, P=0.0035). The concurrent pRT group had a longer mTTF compared with the previous pRT group and similar outcomes to the no RT group. In the previous pRT group, 26.9% of the patients experienced immune-related adverse events compared with 40.1% of patients in the no RT group. Despite the use of pRT during immunotherapy being considered safe, the results of the present study suggest that pRT has a negative effect on immune balance.
Identifiants
pubmed: 31929875
doi: 10.3892/br.2019.1265
pii: BR-0-0-1265
pmc: PMC6951237
doi:
Types de publication
Journal Article
Langues
eng
Pagination
59-67Informations de copyright
Copyright: © Bersanelli et al.
Références
J Am Coll Surg. 1995 Sep;181(3):193-201
pubmed: 7670677
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
J Exp Clin Cancer Res. 2017 Aug 11;36(1):108
pubmed: 28800754
J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
pubmed: 23291374
Ann Immunol (Paris). 1983 Jan-Feb;134C(1):149-57
pubmed: 6222688
Crit Rev Oncol Hematol. 2017 Dec;120:86-92
pubmed: 29198341
Acta Oncol. 2016;55 Suppl 1:79-84
pubmed: 26784139
Ecancermedicalscience. 2019 Mar 28;13:913
pubmed: 31123496
J Oncol Pharm Pract. 2019 Apr;25(3):663-673
pubmed: 29996738
Cancer Med. 2018 Nov;7(11):5505-5513
pubmed: 30311424
Int Immunopharmacol. 2003 Aug;3(8):1093-1104
pubmed: 12860166
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Eur J Cancer. 2019 Jan;107:79-85
pubmed: 30551078
Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):415-28
pubmed: 25837904
JAMA Oncol. 2019 Jul 11;:
pubmed: 31294749
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Int Med Res. 2018 May;46(5):1876-1883
pubmed: 29552952
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):368-75
pubmed: 25754629
JAMA Dermatol. 2013 Oct;149(10):1150-7
pubmed: 23945633
Int J Radiat Biol Relat Stud Phys Chem Med. 1980 Apr;37(4):415-28
pubmed: 6968725
Ther Adv Med Oncol. 2018 Jan 18;10:1758834017742575
pubmed: 29383033
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Radiother Oncol. 2019 Jan;130:104-112
pubmed: 30241791
Clin Lung Cancer. 2015 Sep;16(5):325-33
pubmed: 25862554
Melanoma Res. 2017 Oct;27(5):485-491
pubmed: 28858075
J Hematol Oncol. 2018 Aug 16;11(1):104
pubmed: 30115069
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Lancet Oncol. 2017 Jul;18(7):895-903
pubmed: 28551359
Clin Exp Metastasis. 2014 Jun;31(5):543-51
pubmed: 24682604
Immunotherapy. 2018 Oct;10(14):1229-1239
pubmed: 30326787
Radiology. 1969 Aug;93(2):410-2
pubmed: 5822721
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Crit Rev Oncol Hematol. 2018 Mar;123:42-51
pubmed: 29482778